Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believing.
J Immunother Cancer
; 12(6)2024 Jun 17.
Article
in En
| MEDLINE
| ID: mdl-38886116
ABSTRACT
The purpose of this commentary is to highlight the high occurrence of clinical pseudoprogression and delayed responses that have been observed to date with the locally injected oncolytic adenovirus, AdAPT-001, currently in a Phase 1/2 clinical trial (NCT04673942) for the treatment of treatment-refractory tumors. Not surprisingly, these have led to confusion about response assessment and whether to continue patients on treatment. AdAPT-001 carries a transforming growth factor (TGF)-beta trap (TGF-ß), which sequesters TGF-ß, a cytokine that potently regulates inflammation, fibrosis, and immunosuppression in cancer. Pseudoprogression (PsP) or progression prior to response or stabilization, has been widely recognized with radiotherapy for primary brain tumors and immune checkpoint inhibitors (ICIs). PsP has also been described and documented in the context of oncolytic virotherapy but perhaps to a lesser extent. However, repeated intratumoral injections with these immunostimulatory agents may induce a more intense immune response and release more antigenic epitopes than with ICIs, for example, which are strictly T-cell directed rather than also tumor-directed like AdAPT-001.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Disease Progression
/
Oncolytic Virotherapy
Limits:
Humans
Language:
En
Journal:
J Immunother Cancer
Year:
2024
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom